Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B. Arzoumanian V, et al. Among authors: sawyer j. Leukemia. 2008 Apr;22(4):850-5. doi: 10.1038/sj.leu.2405091. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200039 Free PMC article.
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Shaughnessy J, et al. Among authors: sawyer j. Blood. 2003 May 15;101(10):3849-56. doi: 10.1182/blood-2002-09-2873. Epub 2003 Jan 16. Blood. 2003. PMID: 12531801 Free article.
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Shaughnessy J Jr, et al. Among authors: sawyer j. Br J Haematol. 2003 Jan;120(1):44-52. doi: 10.1046/j.1365-2141.2003.03948.x. Br J Haematol. 2003. PMID: 12492575 Free article.
The molecular classification of multiple myeloma.
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. Zhan F, et al. Among authors: sawyer j. Blood. 2006 Sep 15;108(6):2020-8. doi: 10.1182/blood-2005-11-013458. Epub 2006 May 25. Blood. 2006. PMID: 16728703 Free PMC article.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. Shaughnessy JD Jr, et al. Among authors: sawyer j. Blood. 2007 Mar 15;109(6):2276-84. doi: 10.1182/blood-2006-07-038430. Epub 2006 Nov 14. Blood. 2007. PMID: 17105813 Free article.
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Walker R, et al. Among authors: sawyer j. J Clin Oncol. 2007 Mar 20;25(9):1121-8. doi: 10.1200/JCO.2006.08.5803. Epub 2007 Feb 12. J Clin Oncol. 2007. PMID: 17296972 Clinical Trial.
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Barlogie B, et al. Among authors: sawyer j. Blood. 2008 Jan 1;111(1):94-100. doi: 10.1182/blood-2007-06-097444. Epub 2007 Sep 25. Blood. 2008. PMID: 17895401 Free PMC article.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Usmani SZ, et al. Among authors: sawyer j. Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19. Blood. 2013. PMID: 23603914 Free PMC article.
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Barlogie B, et al. Among authors: sawyer j. Blood. 1999 Jan 1;93(1):55-65. Blood. 1999. PMID: 9864146 Free article. Clinical Trial.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Desikan R, et al. Among authors: sawyer j. Blood. 2000 Jun 15;95(12):4008-10. Blood. 2000. PMID: 10845942 Free article. Clinical Trial.
874 results